Connect your AI

Rhythm Pharmaceuticals, Inc. RYTM Price / book

Price / book at other companies

Eli LillyLLY

26.3×-20.7×

Mirum Pharmaceuticals, Inc.MIRM

23×+13.5×

Arrowhead ResearchARWR

14.3×+11.7×

AlkermesALKS

3.4×-0.2×

Praxis Precision Medicines, Inc.PRAX

6.4×+4.6×

TG TherapeuticsTGTX

9.1×-17.0×

Other financials

Income statement

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Balance sheet

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Cash flow

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Valuation

Market cap$6.64B+77.3%

Enterprise value$6.69B+78.4%

P/S30.6×+3.2×

Profitability

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Returns & leverage

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Where this comes from

Calculated from Rhythm Pharmaceuticals, Inc.’s reported figures.

market cap/total stockholders equity=48.3×

Based on the most recent quarter.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s price / book?: Rhythm Pharmaceuticals, Inc. (RYTM) reported price / book of 48.3× in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s price / book changed year-over-year?: Rhythm Pharmaceuticals, Inc.'s price / book decreased by 72.7% year-over-year, from 176.8× to 48.3×.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s price / book?: Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s price / book has grown at a 41.8% compound annual growth rate (CAGR), from 9× to 51.4×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.